Flufenamic acid-d4
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Flufenamic acid-d4
UNSPSC Description:
Flufenamic acid-d4 is deuterium labeled Flufenamic acid. Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (COX), activates AMPK, and also modulates ion channels, blocking chloride channels and L-type Ca2+ channels, modulating non-selective cation channels (NSC), activating K+ channels. Flufenamic acid binds to the central pocket of TEAD2 YBD and inhibits both TEAD function and TEAD-YAP-dependent processes, such as cell migration and proliferation.Target Antigen:
AMPK; Calcium Channel; Chloride Channel; COX; Isotope-Labeled Compounds; Parasite; Potassium ChannelType:
Isotope-Labeled CompoundsRelated Pathways:
Anti-infection;Epigenetics;Immunology/Inflammation;Membrane Transporter/Ion Channel;Neuronal Signaling;Others;PI3K/Akt/mTORApplications:
COVID-19-immunoregulationField of Research:
Inflammation/ImmunologySolubility:
10 mM in DMSOSmiles:
OC(C(C([2H])=C([2H])C([2H])=C1[2H])=C1NC2=CC(C(F)(F)F)=CC=C2)=OMolecular Weight:
285.25References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Guinamard R, et al. Flufenamic acid as an ion channel modulator. Pharmacol Ther. 2013 May;138(2):272-84.|[3]Pobbati AV, et al. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. Structure. 2015;23(11):2076-2086.|[4]Pongkorpsakol P, et al. Cellular mechanisms underlying the inhibitory effect of flufenamic acid on chloride secretion in human intestinal epithelial cells. J Pharmacol Sci. 2017 Jun;134(2):93-100.|[5]Pongkorpsakol P, et al. Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation. Eur J Pharmacol. 2017 Mar 5;798:94-104.Shipping Conditions:
Room temperatureClinical Information:
No Development ReportedCAS Number:
1185071-99-1
